The use of bronchial thermoplasty resulted in improvements in asthma control and reductions in the use of corticosteroid maintenance therapies in patients with asthma.
The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.
In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS.
AAAAI 2020, News
High doses of inhaled corticosteroids were associated with lower levels of eosinophils, which may interfere with the recommendation of some monoclonal antibodies in asthma treatment.
ACR 2019, News
Researchers evaluated the efficacy and safety of guselkumab in patients with active psoriatic arthritis who were biologic-naive or treated with prior tumor necrosis factor inhibitors.
Patients with both asthma and allergies had a significant increase in the number of prescriptions dispensed for controller medications.
Disrupting regular combination inhaled corticosteroid therapy refills increased hospitalizations and exacerbations.
Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.
Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
Children with asthma who experience chronic oral glucocorticoid exposure may have significant morbidities, including adrenal suppression, recurrent pneumonia, and behavioral problems.